Industry-academic partnerships: an approach to accelerate innovation

Chen, Jennwood; Pickett, Timothy; Langell, Ashley; Trane, Ashley; Charlesworth, Brian; Løken, K.-P.; Lombardo, Sarah; Langell, John T.

doi:10.1016/j.jss.2016.06.029

Cited by 15 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It consists of probes attached to a simple control box by cables and an enlarged probe tip to accommodate variable lesion sizes [108] , [109] . The Liger Thermo Coagulator is a battery-powered, portable, cordless, and handheld thermocoagulation device currently in clinical trials to validate its effectiveness in treating cervical precancerous lesions [110] .…”

Section: Tools For the Treatment Of Cancermentioning

confidence: 99%

The Role of Affordable, Point-of-Care Technologies for Cancer Care in Low- and Middle-Income Countries: A Review and Commentary

Haney

Tandon

Divi

et al. 2017

IEEE J. Transl. Eng. Health Med.

View full text Add to dashboard Cite

As the burden of non-communicable diseases such as cancer continues to rise in low- and middle-income countries (LMICs), it is essential to identify and invest in promising solutions for cancer control and treatment. Point-of-care technologies (POCTs) have played critical roles in curbing infectious disease epidemics in both high- and low-income settings, and their successes can serve as a model for transforming cancer care in LMICs, where access to traditional clinical resources is often limited. The versatility, cost-effectiveness, and simplicity of POCTs warrant attention for their potential to revolutionize cancer detection, diagnosis, and treatment. This paper reviews the landscape of affordable POCTs for cancer care in LMICs with a focus on imaging tools, in vitro diagnostics, and treatment technologies and aspires to encourage innovation and further investment in this space.

show abstract

Section: Tools For the Treatment Of Cancermentioning

confidence: 99%

The Role of Affordable, Point-of-Care Technologies for Cancer Care in Low- and Middle-Income Countries: A Review and Commentary

Haney

Tandon

Divi

et al. 2017

IEEE J. Transl. Eng. Health Med.

View full text Add to dashboard Cite

show abstract

“…Despite the emergence and endorsement of innovative digital health AICs, collaboration remains understudied (5,(14)(15)(16)(17). Little is known from the real world (18), particularly the mechanisms of collaboration, contextual factors, and partnership dynamics among highly collaborative organizations.…”

Section: Introductionmentioning

confidence: 99%

“It depends:” a qualitative study on digital health academic-industry collaboration

Ford

Leiferman

Sobral

et al. 2021

mHealth

View full text Add to dashboard Cite

Background: Academic-industry collaborations (AICs) are endorsed to alleviate challenges in digital health, but partnership experiences remain understudied. The qualitative study's objective investigated collaboration experiences between academic institutions and digital health companies.Methods: A phenomenology methodology captured experiences of AICs, eliciting perspectives from academic researchers and industry affiliates (e.g., leadership, company investigators). Semi-structured interviews probed eligible collaborators about their experiences in digital health. Analysts coded and organized data into significant statements reaching thematic saturation.Results: Participants (N=20) were interviewed from 6 academic institutions and 14 unique industry partners. Seven themes emerged: (I) Collaboration evolves with time, relationships, funding, and evidence; (II) Collaboration demands strong relationships and interpersonal dynamics; (III) Operational processes vary across collaborations; (IV) Collaboration climate and context matters; (V) Shared expectations lead to a better understanding of success; (VI) Overcoming challenges with recommendations; (VII) Collaboration may help navigate the global pandemic. Conclusions: Digital health academic industry collaboration demands strong relationships, requiring flexible mechanisms of collaboration and cultural fit. Diverse models of collaboration exist and remain dependent on contextual factors. While no collaboration conquers all challenges in digital health, AICs may serve as a facilitator for improved digital health products, thus advancing science, promoting public health, and benefiting the economy.

show abstract

“…However, it treats only superficial lesions (up to a depth of 3.5 mm), and it requires access to electricity 11 . While battery-powered hand-held thermo-coagulators have been developed, these devices cost approximately $500–$1000 and require a consistent supply of batteries 12 . Cryotherapy, which induces necrosis by freezing malignant tissue, does not require access to electricity, but requires specialized equipment and potentially hard-to-supply compressed gas tanks and is not portable 13 , 14 .…”

Section: Introductionmentioning

confidence: 99%

Development of enhanced ethanol ablation as an alternative to surgery in treatment of superficial solid tumors

Morhard

Nief

Barrero

et al. 2017

Sci Rep

View full text Add to dashboard Cite

While surgery is at the foundation of cancer treatment, its access is limited in low-income countries. Here, we describe development of a low-cost alternative therapy based on intratumoral ethanol injection suitable for resource-limited settings. Although ethanol-based tumor ablation is successful in treating hepatocellular carcinomas, the necessity for multiple treatments, injection of large fluid volumes, and decreased efficacy in treatment of non-capsulated tumors limit its applicability. To address these limitations, we investigated an enhanced ethanol ablation strategy to retain ethanol within the tumor through the addition of ethyl cellulose. This increases the viscosity of injected ethanol and forms an ethanol-based gel-phase upon exposure to the aqueous tumor environment. This technique was first optimized to maximize distribution volume, using tissue-simulating phantoms. Then, chemically-induced epithelial tumors in the hamster cheek pouch were treated. As controls, pure ethanol injections of either four times or one-fourth the tumor volume induced complete regression of 33% and 0% of tumors, respectively. In contrast, ethyl cellulose-ethanol injections of one-fourth the tumor volume induced complete regression in 100% of tumors. These results contribute to proof-of-concept for enhanced ethanol ablation as a novel and effective alternative to surgery for tumor treatment, with relevance to resource-limited settings.

show abstract

Industry-academic partnerships: an approach to accelerate innovation

Cited by 15 publications

References 14 publications

The Role of Affordable, Point-of-Care Technologies for Cancer Care in Low- and Middle-Income Countries: A Review and Commentary

The Role of Affordable, Point-of-Care Technologies for Cancer Care in Low- and Middle-Income Countries: A Review and Commentary

“It depends:” a qualitative study on digital health academic-industry collaboration

Development of enhanced ethanol ablation as an alternative to surgery in treatment of superficial solid tumors

Contact Info

Product

Resources

About